Hero

News & Events

Mestag in the News
BioCentury Article: Mestag: Attacking Tumors from Within

Fierce Biotech: Merck & Co. signs $1.9B deal with Mestag to explore fibroblast therapies for inflammation

Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic

Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia

Mestag Therapeutics Appoints Dr. Matthew Sleeman as Chief Scientific Officer

Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform

December 9, 2024

Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General Counsel

November 13, 2024

View All Press Releases

Keystone Symposia on Cancer Immunotherapy – Québec, Canada

March 15-18, 2026

Conference Website

BioEquity Europe – Prague

Conference Website